Herndon, Virginia (PRWEB) February 22, 2022 Rare diseases affect an estimated 350 million people globally spanning more than 7,000 known conditions. And
5th Annual Wow! Or Yeow?!: FDA Outlook for 2022 and Beyond FREE Webinar - US Politics Today einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
Published: May 21, 2021 By Alex Keown
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
AavantiBio – Jessie Hanrahan was named chief regulatory officer of AavantiBio. Hanrahan will oversee global regulatory affairs for AavantiBio’s diversified pipeline of gene therapy programs targeting rare diseases with significant unmet medical needs. Most recently, she was Vice President of Regulatory Science at bluebird bio, Inc. Prior to bluebird bio, Hanrahan held positions of increasing responsibility at Genzyme Corp. where she worked across the oncology, multiple sclerosis and rare disease therapeutic areas. Earlier in her career, Hanrahan worked at Boston Scientific Corporation.